Latest News
Biogen and Ionis Provide Update on Nusinersen (IONIS-SMNRx)
Biogen and Ionis Pharmaceuticals recently provided an update on the clinical development of nusinersen (IONIS-SMNRx), which is currently being tested in Phase 3 clinical trials: Dear members of the SMA […]
Read More ›Abstract Submission Opens for 2016 SMA Researcher Meeting
Abstract submission is now open for the 2016 SMA Researcher Meeting, which will be held June 16-18 as part of the Annual SMA Conference in Anaheim, CA. Interested researchers may […]
Read More ›Roche Announces New Clinical Trial of RG7916
Roche, along with partners PTC Therapeutics and the SMA Foundation, recently provided the following update on the development of RG7800 and on a new clinical trial planned for RG7916: “Dear […]
Read More ›AveXis Announces the Completion of Enrollment for Phase 1 Gene Therapy Trial
AveXis has announced that they have completed enrollment in a Phase 1 study testing systemic delivery of gene therapy for SMA. The trial has enrolled a total of 15 patients […]
Read More ›Cytokinetics Opens Enrollment for Phase 2 Trial
Cytokinetics has opened enrollment for a Phase 2 study testing CK-2127107 in teens and adults with SMA type II, III or IV. We are excited to see the continued progress […]
Read More ›Cure SMA Funding Leads to 18 New Research Publications in 2015
An important goal of our research funding strategy is to share scientific findings with the broader scientific community. To help accomplish this goal, scientists who receive Cure SMA funding often […]
Read More ›